Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.44 |
| ▸ | BCHE | P06276 | 8/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22198572 | 0.80 | CHRM2 (0.35) | — | |
| SCHEMBL10245401 | 0.74 | ALDH1A1 (0.60) | — | |
| SCHEMBL20773975 | 0.72 | ALDH1A1 (0.38) | — | |
| SCHEMBL9529357 | 0.70 | CHRM2 (0.52) | — | |
| SCHEMBL20774032 | 0.69 | ALDH1A1 (0.37) | — | |
| SCHEMBL6243058 | 0.67 | TSHR (0.36) | — | |
| SCHEMBL10741444 | 0.67 | PRMT6 (0.61) | ACHEBCHEPRMT6HRH2 | |
| SCHEMBL11366257 | 0.66 | ACHE (0.61) | ACHEBCHEHRH2 | |
| SCHEMBL11360362 | 0.66 | PRMT6 (0.55) | ACHEBCHEPRMT6HRH2 | |
| SCHEMBL13202820 | 0.65 | ACHE (0.75) | ACHEBCHEPRMT6HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384946-B2 | N-{4-[2-([11-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-11-yl)-ethyl]-cyclohexyl}-2-[2-({4-[2-([11-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-11-yl)-ethyl]-cyclohexylcarbamoyl}}-methyl)-phenyl]]-acetamide; respiratory system disorders: COPD, bronchitis, asthma, pulmonary fibrosis, emphysema, rhinitis | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-7384946-B2 | N-{4-[2-([11-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-11-yl)-ethyl]-cyclohexyl}-2-[2-({4-[2-([11-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-11-yl)-ethyl]-cyclohexylcarbamoyl}}-methyl)-phenyl]]-acetamide; respiratory system disorders: COPD, bronchitis, asthma, pulmonary fibrosis, emphysema, rhinitis | GLAXO GROUP LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149598-A1 | M3 muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | ACHE 23/4885BCHE 80/4885PRMT6 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.